In this episode we welcome Rob Roscow, Co-Founder & Chief Scientific Officer at Mydecine Innovations Group.
Mydecine has government, military, and academic research contracts across numerous countries and is heavily invested in development of a novel molecule pipeline that includes treatments intended for smoking cessation and treatment of PTSD.
I had a chance to meet Rob and the Mydecine team in-person at the 2021 Telluride Mushroom Festival, which was sponsored by Mydecine.
This episode dives into the Mydecine drug development pipeline and the entourage effect of mushrooms through a biopharmaceutical lens.
It's an arena of study which I am largely unfamiliar with, but which is becoming increasingly important in lobbying for the mainstream acceptance and regulatory scrutiny of psychedelic medicines as legitimate and effective therapeutic tools.
Hosted on Acast. See acast.com/privacy for more information.